Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Grunenthal GmbH v. Alkem Laboratories Limited, No. 17-1153 (Fed. Cir. Mar. 28, 2019)

Affirmed
Invalidity (§ 102/§ 103) Infringement Claim Construction
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 17-1153
Also Docketed
No. 17-2048, No. 17-2049, No. 17-2050 (consolidated; same document)
Decided
March 28, 2019
Judge
Reyna, J.
Document
Precedential Opinion
Length
23 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Alkem Laboratories Limited, Hikma Pharmaceuticals International Limited, and Hikma Pharmaceuticals USA Inc. appeal the judgment of the district court that U.S. Pa- tent No. 7,994,364 is not invalid for obviousness or lack of utility. Grünenthal GmbH and Assertio Therapeutics, Inc., formerly Depomed, Inc., cross -appeal the finding that Hikma Pharmaceuticals International Limited, Hikma Pharmaceuticals USA Inc., and Actavis Elizabeth LLC do GRUNENTHAL GMBH v. ALKEM LABORATORIES LIMITED 3 not infringe U.S. Patent No. 8,536,130.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error